Next Phase Newsletter

An angel fund based in Canada is very active in their portfolio companies’ development, and is looking to add value through augmenting management, strategy, operations, etc. The firm makes initial investments in the range of $250K – $750K, and is flexible with structure, using both convertible loans as well as straight equity. The group is focused on seed and Series A opportunities and typically looks to lead these deals, but may also invest with a syndicate of other angels and VCs. Although the firm is exclusively focused on Canadian companies, the group has deep connections with medtech and institutional partners across North America and Israel.

The firm is focused on the medical technology and diagnostics sectors and is generally agnostic to technology type, but has specific interest and expertise in the imaging space. The group also favors surgical devices, minimally invasive tools and in-vitro diagnostics. The group only evaluates class I devices and those with 510(k) regulatory pathways, and does not invest in devices/diagnostics that require a PMA. The firm will invest at the earliest stages of development.

The firm is open to working with all entrepreneurs and will invest in companies with incomplete management teams, working to fill in and build out key management positions.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment group founded by Chinese medical device experts seeks to allocate 5-20 Million RMB (0.7-3 Million USD) in various early stage life science opportunities. The firm seeks to make several investments in the upcoming year and focusing on opportunities raising angel, pre-A, Series A, and B rounds. The firm seeks to make use of their founders’ expertise and successes in the medical device industry to help guide their investments towards growth and success. The firm is investing out of a CNY fund and as a result, is currently focused on companies willing to start a joint venture in China.

The firm is primarily interested in medical devices and in vitro diagnostic (IVD) technologies and/or companies. More specifically, they’re interested in opportunities in areas related to cardiology, neuromodulation, in vitro diagnostics, and imaging as that is where they have the most expertise. However, they are willing to look at other areas as well so long as the opportunity is interesting and has the potential to be developed. The firm is also interested in investing in R&D services as well. The firm’s most recent investment was in a company that utilized AI to process images in order for better and faster diagnoses.

The firm heavily prefers that the company has a China angle to work with. They believe that they can contribute more to companies who wish to work in China through connections they have already made such as through helping acquire non-dilutive funds from the government of China and utilizing various connections in industrial parks across China. The firm also wishes to work with companies that are willing to work with the partners at the firm so that they can utilize their prior experiences to help the companies grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early-stage investment and development firm located in the USA has more than $300 million in assets and operates under an evergreen structure. The firm is flexible in investment size and structure, but prefer initial investments in the $1-5M range and the firm reserves additional funds for the subsequent funding of successful companies.

The firm invests in medical devices and research tools. For medical devices, the firm prefers those that can be approved under PMA guidelines. For research tools, the firm invests in technologies that enhance and enable the discovery and manufacture of therapeutics and diagnostics.

The firm seeks to invest in small, early-stage companies with a lean but strong and qualified management/execution team. The firm prefers to invest in companies in the U.S., but will consider opportunities in Europe, Israel and Australia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A US-based VC fund founded in 2016 and based in is investing out of a $261M fund. Within the life sciences, the firm is interested in therapeutics, medical devices, digital health and healthcare IT companies. The firm generally invests in Series B and later rounds and can invest anywhere from $1-20M in the initial check, and may participate in follow-on rounds. The firm is generally focused on investing in companies based in North America but will consider global companies if they have a large presence in the US and are focused on the US market.

The firm will invest in therapeutics, medical devices, digital health and healthcare IT companies. Within therapeutics, the firm is seeking companies in IND or later stages. In addition, the firm is interested in platform technologies, and will also invest in AI or machine learning-based drug discovery companies. The firm will not invest in single asset or single modality companies. For medical devices, the firm primarily invests in 510K pathway devices that are FDA approved. For digital health and healthcare IT companies, the firm is primarily focused on companies with B2B services, and will not invest in digital therapeutics.

The firm is willing to lead or co-invest, but will generally take a board seat if they lead the investment round.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A digital health investment company was launched by a leading pharmaceutical company in 2016. The firm focuses on the digital health space and invest in companies that use data and intelligence derived from data to solve important healthcare problems. The firm’s investments range dependent on the opportunity and focus mainly on Series A rounds. For earlier stage companies, the firm has the ability to both lead and co-invest. The firm focuses on companies based in the U.S., but is open to investing globally.

The firm focuses on digital health technologies and solutions that aim to improve the quality and the delivery of patient care. The firm is especially interested in technology with a software component, such as those that control patient care through monitoring medications and therapies, as well as technology with a big data component. The firm will only look at devices if they have an information component and/or generate data, and is interested in technology with machine-learning applications. Based on all the criteria, the firm is indication agnostic.

The firm is a very active investor that seeks to be fully involved in their portfolio companies. The firm will take a board seat after the investment and will help companies fill management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A venture capital firm based in Taiwan is investing in breakthrough technologies changing healthcare. The firm invests from seed-Series A and the fund’s LP’s include groups in the healthcare sector.

The firm invests in early-stage life science startups with a focus on breakthrough technologies and sciences in healthcare. This includes genomic and synthetic biology technologies, digital health, ML/AI, therapeutics and diagnostics. The firm focuses on pre-IND assets in therapeutics. For technologies regulated as medical devices, the firm focuses on smart medical devices in the pre-commercial stage.

The firm have a strong clinical perspective and has the capability to help portfolio companies develop clinical resources, and has helped academic scientists form companies to commercialize their discoveries.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A venture capital firm based in USA has about one third of their investments in healthcare. The firm is a fairly opportunistic investor, and looks for companies that have a strong IP position and a strong management team. The firm invests opportunistically in therapeutics, medical devices, diagnostics and, to a lesser degree, digital health technologies, but they get most excited about companies leveraging new technologies and/or with the potential for platform business models.  The firm generally invests in seed-series A rounds , investing $500k-3M in rounds generally in the range of $2 to $15 million. The firm prefers to invest companies that have some clinical data. The firm will invest globally, but prefers to invest in companies based in the US.

The firm invests opportunistically in therapeutics, medical devices, diagnostics and, to a lesser degree, digital health technologies. Historically, the firm has invested in health technologies driven by breakthroughs in AI, materials science or nanotechnology, and will not invest in a digital technology that does not have strong IP. The firm is generally agnostic to indication. The firm generally does not invest in consumer-facing/telehealth-related digital health companies.

The firm looks for companies with strong IP and management teams. The firm is willing to lead or co-invest, but will generally not participate in rounds larger than $30M. When acting as a lead investor, the firm is a very active investor, and plays a large role in helping company development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.